Literature DB >> 7725103

Expression cloning of a protective Leishmania antigen.

E Mougneau1, F Altare, A E Wakil, S Zheng, T Coppola, Z E Wang, R Waldmann, R M Locksley, N Glaichenhaus.   

Abstract

Parasite-specific CD4+ T cells have been shown to transfer protection against Leishmania major in susceptible BALB/c mice. An epitope-tagged expression library was used to identify the antigen recognized by a protective CD4+ T cell clone. The expression library allowed recombinant proteins made in bacteria to be captured by macrophages for presentation to T cells restricted to major histocompatibility complex class II. A conserved 36-kilodalton member of the tryptophan-aspartic acid repeat family of proteins was identified that was expressed in both stages of the parasite life cycle. A 24-kilodalton portion of this antigen protected susceptible mice when administered as a vaccine with interleukin-12 before infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7725103     DOI: 10.1126/science.7725103

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  113 in total

1.  KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis.

Authors:  Yasuyuki Goto; Ajay Bhatia; Vanitha S Raman; Hong Liang; Raodoh Mohamath; Alessandro F Picone; Silvia E Z Vidal; Thomas S Vedvick; Randall F Howard; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2011-06-01

2.  Detection of HLA class II-dependent T helper antigen using antigen phage display.

Authors:  R Somasundaram; K Satyamoorthy; L Caputo; H Yssel; D Herlyn
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

3.  The Toxoplasma gondii peptide AS15 elicits CD4 T cells that can control parasite burden.

Authors:  Harshita Satija Grover; Nicolas Blanchard; Federico Gonzalez; Shiao Chan; Ellen A Robey; Nilabh Shastri
Journal:  Infect Immun       Date:  2012-07-09       Impact factor: 3.441

4.  CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung.

Authors:  Cyrille Mionnet; Vanessa Buatois; Akira Kanda; Valerie Milcent; Sebastien Fleury; David Lair; Marie Langelot; Yannick Lacoeuille; Edith Hessel; Robert Coffman; Antoine Magnan; David Dombrowicz; Nicolas Glaichenhaus; Valerie Julia
Journal:  Nat Med       Date:  2010-10-31       Impact factor: 53.440

5.  Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.

Authors:  P C Melby; J Yang; W Zhao; L E Perez; J Cheng
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

6.  Heterogeneity of wild Leishmania major isolates in experimental murine pathogenicity and specific immune response.

Authors:  C Kébaïer; H Louzir; M Chenik; A Ben Salah; K Dellagi
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

7.  T-cell expression cloning of Porphyromonas gingivalis genes coding for T helper-biased immune responses during infection.

Authors:  Reginaldo B Gonçalves; Onir Leshem; Karen Bernards; John R Webb; Philip P Stashenko; Antonio Campos-Neto
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 8.  Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis.

Authors:  Malcolm S Duthie; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2017-07-05

9.  Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response.

Authors:  E Handman; F M Symons; T M Baldwin; J M Curtis; J P Scheerlinck
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

10.  CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge.

Authors:  S Gurunathan; K R Irvine; C Y Wu; J I Cohen; E Thomas; C Prussin; N P Restifo; R A Seder
Journal:  J Immunol       Date:  1998-11-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.